Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
31 participants
INTERVENTIONAL
2014-02-28
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
C4 Extreme
One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
C4 Extreme
Pre-Workout Dietary Supplement
C4 Extreme (without Advantra Z)
One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
C4 Extreme (without Advantra Z
Pre-Workout Dietary Supplement
Placebo
One dose of flavored placebo (powder mixed with water)
Placebo
Pre-Workout Dietary Supplement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
C4 Extreme
Pre-Workout Dietary Supplement
C4 Extreme (without Advantra Z
Pre-Workout Dietary Supplement
Placebo
Pre-Workout Dietary Supplement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* you will need to have at least six months immediate prior history of resistance training on the bench press and leg press or squat;
Exclusion Criteria
* you are currently using prescription medications;
* you have an intolerance to caffeine and/or other natural stimulants;
* you are pregnant or a lactating female or plan to become pregnant with the next month;
* you have a history of smoking;
* you drink excessively (i.e., 12 drinks per week or more);
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nutrabolt
INDUSTRY
Texas A&M University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard B Kreider, PhD
Role: PRINCIPAL_INVESTIGATOR
Texas A&M University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Exercise & Sport Nutrition Laboratory
College Station, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jung YP, Earnest CP, Koozehchian M, Galvan E, Dalton R, Walker D, Rasmussen C, Murano PS, Greenwood M, Kreider RB. Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance. J Int Soc Sports Nutr. 2017 Jan 12;14:3. doi: 10.1186/s12970-016-0159-2. eCollection 2017.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2014-0022FX
Identifier Type: -
Identifier Source: org_study_id